FUL.L Regulatory News (FUL)

7 Sep 2007 07:01

Fulcrum Pharma PLC07 September 2007 7th September 2007 FULCRUM PHARMA PLC ("the Group" or "the Company") Fulcrum and LORENZ in strategic alliance to develop and deliver "Creative eRegulatory SolutionsTM" Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory servicescompany is pleased to announce the intent to form a strategic alliance withLORENZ Life Sciences Group. Fulcrum is committed to developing new products and services which enable Pharmaand Biotech companies to achieve faster regulatory approval of new medicines.LORENZ develops and markets software solutions for the life sciences industrythat are mainly geared towards submission assembly, review, publishing,validation and management for regulated environments. LORENZ and Fulcrum believethat tailored IT solutions are critically important for ensuring the quality ofpharmaceutical regulatory submissions and, if designed and appliedappropriately, can have a dramatic impact on the time to regulatory submissionand approval. As a first step in the strategic alliance, the two companies have agreed toestablish a joint sales and marketing campaign in North America and Europe toprovide tailored e-publishing solutions in this growing market. The jointproduct offering will combine the strategic regulatory and e-publishing skillsof Fulcrum with the submission management software solutions developed byLORENZ. Together, the two companies will offer Creative eRegulatory SolutionsTMin a cost-effective and tailored approach to new and existing clients. Jon Court, Chief Executive of Fulcrum Pharma, said: "Together we will be wellpositioned to meet the increasing demand for regulatory services which comprisean e-publishing component. The alliance with LORENZ will increase our capacityto deliver e-products to our clients and enhance the reach of our regulatorybusiness. We look forward to this exciting partnership and the development of aseries of new regulatory products and services" Wolfgang Witzel, President of Lorenz, said. "This partnership provides atailored solution to meet our customers' needs, combining the regulatory skillsin Fulcrum with the e-publishing expertise in LORENZ. Working with Fulcrum willenable us to enhance our regulatory product offering in a way that directlybenefits our clients. This is an exciting opportunity for both LORENZ andFulcrum" For further information, please contact: Fulcrum Pharma PLCJon Court, Chief Executive Tel: 0870 710 7152 Seymour PierceJonathan Wright Tel: 0207 107 9000 About Fulcrum Pharma plc Fulcrum Pharma plc is a drug development and regulatory services business thatprovides global expertise to achieve drug development and regulatory approvalmilestones. Fulcrum Pharma offers immediate access to a highly credible, integrateddevelopment team that provides strategic and operational leadership required toensure that new drugs move smoothly from discovery research to product approval Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange havingsuccessfully floated in March 2000. About Lorenz LORENZ Life Sciences Group (www.lorenz.cc) develops and markets softwaresolutions for the Life Sciences market. LORENZ's solutions are gearedspecifically for submission assembly, review, publishing, validation andmanagement. As the number one supplier of submission management systems in theworld for US, European and Japanese submissions, LORENZ is currently the marketleader in producing eCTDs. With over 100 installations in 20 countries, LORENZhas built a reputable customer base. For more information, please contact AndreNeu, aneu@lorenz.cc in Europe and Yaprak Eisinger, yeisinger@lorenz.cc in NorthAmerica. This information is provided by RNS The company news service from the London Stock Exchange